THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF)
that contains sorbitol instead of mannitol is now available from Amgen.
The new formulation has the same clinical safety and efficacy profile
as the mannitol-containing version, but offers additional flexibility with
respect to storage parameters.
Sorbitol-containing Neupogen will remain stable even if exposed to freezing
temperatures, as might occur in transit. The recommended storage temperature
will continue to be 2° to 8° C. However, the gel tray insulation
and freeze watch indicators required with mannitol-containing Neupogen
will be eliminated, allowing for smaller packaging and reduced need for
refrigerator inventory space.